MedTrace Logo

Trazodone for Sleep Disorders in Alzheimer's Disease

NCT01142258 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-10-15

No results posted yet for this study

Summary

The purpose of this study is to determine whether trazodone is effective in the treatment of sleep disorders in Alzheimer's disease (AD).

Conditions

Interventions

DRUG

Trazodone

Trazodone tablets, 50 mg, 10pm (before bedtime) for 14 days.

DRUG

Placebo

Inactive or inert pill which will be used as a comparator

Sponsors & Collaborators

  • Universidade Federal do Paraná

    collaborator OTHER

  • Brasilia University Hospital

    lead OTHER

Principal Investigators

  • Einstein F Camargos, MD, MsC · Brasilia University - Brasilia's University Hospital - Geriatric Medical Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2012-04-30
Completion
2012-08-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01142258 on ClinicalTrials.gov